Upgrades Underperform Hold X

NVRO Nevro

Jefferies

$4.50 $5.85

Upgrades Neutral Overweight X

NVRO Nevro

Piper Sandler

$6 $5.85

Downgrades Eq-Weight Underweight X

NVRO Nevro

Morgan Stanley

$9 $4

Upgrades Sell Neutral X

NVRO Nevro

Citigroup

Upgrades Underperform Peer Perform X

NVRO Nevro

Wolfe Research

Downgrades Mkt Outperform Mkt Perform X

NVRO Nevro

JMP Securities

Downgrades Neutral Underweight X

NVRO Nevro

JP Morgan

Downgrades Eq Weight Underweight X

NVRO Nevro

Wells Fargo

$13 $5.50

Downgrades Neutral Sell X

NVRO Nevro

Citigroup

$13.50 $9

Downgrades Outperform Perform X

NVRO Nevro

Oppenheimer

Downgrades Outperform Sec Perform X

NVRO Nevro

RBC Capital Mkts

$23 $20

Downgrades Buy Hold X

NVRO Nevro

Canaccord Genuity

$23

Initiated Neutral X

NVRO Nevro

Robert W. Baird

$26

Initiated Outperform X

NVRO Nevro

RBC Capital Mkts

$40

Upgrades Perform Outperform X

NVRO Nevro

Oppenheimer

$40

Initiated Neutral X

NVRO Nevro

Mizuho

$40

Downgrades Buy Neutral X

NVRO Nevro

Citigroup

$40

Downgrades Neutral Underweight X

NVRO Nevro

Piper Sandler

$42 $38

Upgrades Hold Buy X

NVRO Nevro

Canaccord Genuity

$41 $67

Downgrades Overweight Eq Weight X

NVRO Nevro

Wells Fargo

$66 $43

Initiated Underperform X

NVRO Nevro

Jefferies

$31

Upgrades Neutral Buy X

NVRO Nevro

Citigroup

$78

Resumed Hold X

NVRO Nevro

Truist

$72 $80

Downgrades Overweight Eq-Weight X

NVRO Nevro

Morgan Stanley

$140 $100

Downgrades Buy Hold X

NVRO Nevro

Truist

$165 $105

Downgrades Buy Neutral X

NVRO Nevro

Redburn

Downgrades Outperform Neutral X

NVRO Nevro

Robert W. Baird

$188 $150

Initiated Overweight X

NVRO Nevro

Piper Sandler

$190

Upgrades Neutral Buy X

NVRO Nevro

BofA/Merrill

$50 $70

Upgrades Mkt Perform Outperform X

NVRO Nevro

Wells Fargo

$75

Initiated Sell X

NVRO Nevro

UBS

Downgrades Buy Neutral X

NVRO Nevro

BofA/Merrill

Downgrades Overweight Neutral X

NVRO Nevro

JP Morgan

Downgrades Eq-Weight Underweight X

NVRO Nevro

Morgan Stanley

Downgrades Neutral Sell X

NVRO Nevro

Goldman

Downgrades Overweight Eq-Weight X

NVRO Nevro

Morgan Stanley

Reiterated Buy X

NVRO Nevro

Canaccord Genuity

$110 $102

Downgrades Outperform Mkt Perform X

NVRO Nevro

Northland Capital

Downgrades Outperform Mkt Perform X

NVRO Nevro

Wells Fargo

Initiated Neutral X

NVRO Nevro

Goldman

$83

NVRO  Nevro Corp.

Nevro Corp. is a global medical device company. The Company focuses on providing products that improve the quality of life of patients suffering from chronic pain. The Company has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain. Its HF10 therapy is designed to deliver neuromodulation solutions for treating chronic pain. HF10 therapy enables patients to achieve sustained pain relief without paresthesia, thus enabling its patients to avoid the uncomfortable shocking or jolting sensations commonly associated with paresthesia. HF10 therapy relies on consistent anatomical lead placement. As of December 31, 2016, it was investigating the use of HF10 therapy to address additional indications, such as chronic upper limb and neck pain, painful neuropathies and non-surgical refractory back pain. The Senza system is approved to create electrical impulses from 2 hertz (Hz) to 10,000 Hz.